Prostate cancer

Olaparib, a targeted cancer drug discovered and developed with our funding, has been approved for hundreds of patients with certain breast and prostate cancers in England. 

NICE does not recommend olaparib (Lynparza) for people with a type of advanced prostate cancer, as the treatment is not deemed cost-effective

New research has found that using an advanced MRI technique may enable doctors to pinpoint potentially aggressive or fast-growing cancers and guide treatment pathways.

Prostate cancer screening is back in the news, as results from a targeted screening programme are released. But when it comes to yearly checks, are we there yet?

The targeted drug olaparib has been approved for some people with a type of advanced prostate cancer on the NHS in Scotland.

A study published earlier this year uncovered some important differences in people’s experience of visiting the GP.

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

Meet two of the latest Primer Awardees and find out why forensic science and nanomaterials are, in fact, ideal backgrounds for cancer research

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.